{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,23]],"date-time":"2026-07-23T00:03:41Z","timestamp":1784765021546,"version":"3.55.0"},"reference-count":89,"publisher":"Elsevier BV","issue":"3","license":[{"start":{"date-parts":[[2026,8,1]],"date-time":"2026-08-01T00:00:00Z","timestamp":1785542400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2026,8,1]],"date-time":"2026-08-01T00:00:00Z","timestamp":1785542400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2026,8,1]],"date-time":"2026-08-01T00:00:00Z","timestamp":1785542400000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2026,8,1]],"date-time":"2026-08-01T00:00:00Z","timestamp":1785542400000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2026,8,1]],"date-time":"2026-08-01T00:00:00Z","timestamp":1785542400000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2026,8,1]],"date-time":"2026-08-01T00:00:00Z","timestamp":1785542400000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2026,8,1]],"date-time":"2026-08-01T00:00:00Z","timestamp":1785542400000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","theclinics.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Clinics in Liver Disease"],"published-print":{"date-parts":[[2026,8]]},"DOI":"10.1016\/j.cld.2026.04.007","type":"journal-article","created":{"date-parts":[[2026,5,20]],"date-time":"2026-05-20T11:27:27Z","timestamp":1779276447000},"page":"587-599","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":0,"title":["General Hepatology Concerns for the Patient with Cholestatic Liver Disease"],"prefix":"10.1016","volume":"30","author":[{"given":"Maya","family":"Deeb","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Michelle","family":"Ma","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"4","key":"10.1016\/j.cld.2026.04.007_bib1","doi-asserted-by":"crossref","first-page":"253","DOI":"10.1055\/s-0036-1592331","article-title":"A systematic approach to patients with jaundice","volume":"33","author":"Gondal","year":"2016","journal-title":"Semin Interv Radiol"},{"issue":"6","key":"10.1016\/j.cld.2026.04.007_bib2","doi-asserted-by":"crossref","first-page":"5823","DOI":"10.3390\/ijms24065823","article-title":"Molecular and clinical links between drug-induced cholestasis and familial intrahepatic cholestasis","volume":"24","author":"Vitale","year":"2023","journal-title":"Int J Mol Sci"},{"issue":"Suppl 2","key":"10.1016\/j.cld.2026.04.007_bib3","doi-asserted-by":"crossref","first-page":"176","DOI":"10.1159\/000440830","article-title":"IgG4-associated cholangitis--a mimic of PSC","volume":"33","author":"Beuers","year":"2015","journal-title":"Dig Dis"},{"issue":"16","key":"10.1016\/j.cld.2026.04.007_bib4","doi-asserted-by":"crossref","first-page":"1691","DOI":"10.3748\/wjg.v27.i16.1691","article-title":"From hepatitis A to E: a critical review of viral hepatitis","volume":"27","author":"Castaneda","year":"2021","journal-title":"World J Gastroenterol"},{"issue":"1","key":"10.1016\/j.cld.2026.04.007_bib5","doi-asserted-by":"crossref","first-page":"93","DOI":"10.1016\/j.cld.2023.07.002","article-title":"Autoimmune markers in primary biliary cholangitis","volume":"28","author":"Shah","year":"2024","journal-title":"Clin Liver Dis"},{"issue":"9976","key":"10.1016\/j.cld.2026.04.007_bib6","doi-asserted-by":"crossref","first-page":"1460","DOI":"10.1016\/S0140-6736(14)60720-0","article-title":"IgG4-related disease","volume":"385","author":"Kamisawa","year":"2015","journal-title":"Lancet"},{"issue":"7","key":"10.1016\/j.cld.2026.04.007_bib7","doi-asserted-by":"crossref","first-page":"1562","DOI":"10.1111\/liv.15271","article-title":"Symptom patterns in the daily life of PSC patients","volume":"42","author":"van Munster","year":"2022","journal-title":"Liver Int"},{"issue":"1","key":"10.1016\/j.cld.2026.04.007_bib8","doi-asserted-by":"crossref","first-page":"26","DOI":"10.1038\/s41575-022-00687-7","article-title":"Mechanisms of pruritus in cholestasis: understanding and treating the itch","volume":"20","author":"Beuers","year":"2023","journal-title":"Nat Rev Gastroenterol Hepatol"},{"issue":"3","key":"10.1016\/j.cld.2026.04.007_bib9","doi-asserted-by":"crossref","first-page":"995","DOI":"10.1007\/s10620-022-07581-x","article-title":"Impact of pruritus on quality of life and current treatment patterns in patients with primary biliary cholangitis","volume":"68","author":"Mayo","year":"2023","journal-title":"Dig Dis Sci"},{"issue":"7","key":"10.1016\/j.cld.2026.04.007_bib10","doi-asserted-by":"crossref","first-page":"775","DOI":"10.1001\/jamadermatol.2025.1471","article-title":"Nemolizumab for cholestatic pruritus in a patient with liver transplant and primary sclerosing cholangitis","volume":"161","author":"Soto-Canetti","year":"2025","journal-title":"JAMA Dermatol"},{"issue":"1","key":"10.1016\/j.cld.2026.04.007_bib11","doi-asserted-by":"crossref","first-page":"20","DOI":"10.1002\/hep.32599","article-title":"IL-31 levels correlate with pruritus in patients with cholestatic and metabolic liver diseases and is farnesoid X receptor responsive in NASH","volume":"77","author":"Xu","year":"2023","journal-title":"Hepatology"},{"issue":"3","key":"10.1016\/j.cld.2026.04.007_bib12","doi-asserted-by":"crossref","first-page":"1008","DOI":"10.1053\/j.gastro.2010.05.009","article-title":"Lysophosphatidic acid is a potential mediator of cholestatic pruritus","volume":"139","author":"Kremer","year":"2010","journal-title":"Gastroenterology"},{"issue":"5","key":"10.1016\/j.cld.2026.04.007_bib13","doi-asserted-by":"crossref","first-page":"1125","DOI":"10.1016\/S0016-5085(19)31870-0","article-title":"Elevations in skin tissue levels of bile acids in human cholestasis: relation to serum levels and topruritus","volume":"73","author":"Ghent","year":"1977","journal-title":"Gastroenterology"},{"issue":"2","key":"10.1016\/j.cld.2026.04.007_bib14","doi-asserted-by":"crossref","first-page":"143","DOI":"10.1097\/MCG.0000000000001797","article-title":"Pharmacological therapy of pruritus in primary biliary cholangitis: a systematic review and meta-analysis of randomized clinical trials","volume":"57","author":"Medina-Morales","year":"2023","journal-title":"J Clin Gastroenterol"},{"issue":"4","key":"10.1016\/j.cld.2026.04.007_bib15","doi-asserted-by":"crossref","first-page":"1334","DOI":"10.1002\/hep.23821","article-title":"The potent bile acid sequestrant colesevelam is not effective in cholestatic pruritus: results of a double-blind, randomized, placebo-controlled trial","volume":"52","author":"Kuiper","year":"2010","journal-title":"Hepatology"},{"issue":"1","key":"10.1016\/j.cld.2026.04.007_bib16","doi-asserted-by":"crossref","first-page":"145","DOI":"10.1016\/j.jhep.2017.03.022","article-title":"EASL clinical practice guidelines: the diagnosis and management of patients with primary biliary cholangitis","volume":"67","year":"2017","journal-title":"J Hepatol"},{"issue":"1","key":"10.1016\/j.cld.2026.04.007_bib17","doi-asserted-by":"crossref","first-page":"394","DOI":"10.1002\/hep.30145","article-title":"Primary biliary cholangitis: 2018 practice guidance from the American Association for the Study of Liver diseases","volume":"69","author":"Lindor","year":"2019","journal-title":"Hepatology"},{"issue":"8","key":"10.1016\/j.cld.2026.04.007_bib18","doi-asserted-by":"crossref","first-page":"1213","DOI":"10.1111\/apt.14579","article-title":"Low risk of hepatotoxicity from rifampicin when used for cholestatic pruritus: a cross-disease cohort study","volume":"47","author":"Webb","year":"2018","journal-title":"Aliment Pharmacol Ther"},{"key":"10.1016\/j.cld.2026.04.007_bib19","article-title":"Linerixibat in patients with primary biliary cholangitis and cholestatic pruritus (GLISTEN): a randomised, multicentre, double-blind, placebo-controlled, phase 3 trial","author":"Hirschfield","year":"2025","journal-title":"Lancet Gastroenterol Hepatol"},{"issue":"3","key":"10.1016\/j.cld.2026.04.007_bib20","doi-asserted-by":"crossref","first-page":"666","DOI":"10.1002\/hep.21553","article-title":"Sertraline as a first-line treatment for cholestatic pruritus","volume":"45","author":"Mayo","year":"2007","journal-title":"Hepatology"},{"issue":"4","key":"10.1016\/j.cld.2026.04.007_bib21","doi-asserted-by":"crossref","first-page":"1264","DOI":"10.1053\/gast.1997.v113.pm9322521","article-title":"Oral naltrexone treatment for cholestatic pruritus: a double-blind, placebo-controlled study","volume":"113","author":"Wolfhagen","year":"1997","journal-title":"Gastroenterology"},{"issue":"7","key":"10.1016\/j.cld.2026.04.007_bib22","doi-asserted-by":"crossref","first-page":"1528","DOI":"10.1111\/j.1572-0241.2007.01200.x","article-title":"The efficacy and safety of bile acid binding agents, opioid antagonists, or rifampin in the treatment of cholestasis-associated pruritus","volume":"102","author":"Tandon","year":"2007","journal-title":"Am J Gastroenterol"},{"issue":"2","key":"10.1016\/j.cld.2026.04.007_bib23","doi-asserted-by":"crossref","first-page":"294","DOI":"10.1111\/apt.13449","article-title":"The safety and efficacy of nasobiliary drainage in the treatment of refractory cholestatic pruritus: a multicentre European study","volume":"43","author":"Hegade","year":"2016","journal-title":"Aliment Pharmacol Ther"},{"issue":"12","key":"10.1016\/j.cld.2026.04.007_bib24","article-title":"Ursodeoxycholic acid for primary biliary cirrhosis","volume":"12","author":"Rudic","year":"2012","journal-title":"Cochrane Database Syst Rev"},{"issue":"6","key":"10.1016\/j.cld.2026.04.007_bib25","doi-asserted-by":"crossref","first-page":"1492","DOI":"10.1053\/j.gastro.2012.08.004","article-title":"Efficacy of ursodeoxycholic acid in treating intrahepatic cholestasis of pregnancy: a meta-analysis","volume":"143","author":"Bacq","year":"2012","journal-title":"Gastroenterology"},{"issue":"9","key":"10.1016\/j.cld.2026.04.007_bib26","doi-asserted-by":"crossref","first-page":"795","DOI":"10.1056\/NEJMoa2306185","article-title":"Efficacy and safety of elafibranor in primary biliary cholangitis","volume":"390","author":"Kowdley","year":"2024","journal-title":"N Engl J Med"},{"issue":"9","key":"10.1016\/j.cld.2026.04.007_bib27","doi-asserted-by":"crossref","first-page":"783","DOI":"10.1056\/NEJMoa2312100","article-title":"A phase 3 trial of seladelpar in primary biliary cholangitis","volume":"390","author":"Hirschfield","year":"2024","journal-title":"N Engl J Med"},{"issue":"4","key":"10.1016\/j.cld.2026.04.007_bib28","doi-asserted-by":"crossref","first-page":"726","DOI":"10.1016\/j.jhep.2024.04.008","article-title":"Assessment of fatigue and its impact in chronic liver disease","volume":"81","author":"Younossi","year":"2024","journal-title":"J Hepatol"},{"issue":"8","key":"10.1016\/j.cld.2026.04.007_bib29","doi-asserted-by":"crossref","first-page":"2338","DOI":"10.1007\/s10620-019-5457-5","article-title":"Treatment of fatigue in primary biliary cholangitis: a systematic review and meta-analysis","volume":"64","author":"Lee","year":"2019","journal-title":"Dig Dis Sci"},{"issue":"22","key":"10.1016\/j.cld.2026.04.007_bib30","doi-asserted-by":"crossref","DOI":"10.2169\/internalmedicine.7175-21","article-title":"The efficacy of levocarnitine treatment in relieving fatigue in patients with cirrhosis but without overt hepatic encephalopathy","volume":"60","author":"Abe","year":"2021","journal-title":"Intern Med"},{"issue":"1","key":"10.1016\/j.cld.2026.04.007_bib31","doi-asserted-by":"crossref","first-page":"137","DOI":"10.1046\/j.1365-2036.2003.01398.x","article-title":"Oral antioxidant supplementation for fatigue associated with primary biliary cirrhosis: results of a multicentre, randomized, placebo-controlled, cross-over trial","volume":"17","author":"Prince","year":"2003","journal-title":"Aliment Pharmacol Ther"},{"issue":"3","key":"10.1016\/j.cld.2026.04.007_bib32","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0301354","article-title":"High-dose oral thiamine versus placebo for chronic fatigue in patients with primary biliary cholangitis: a crossover randomized clinical trial","volume":"19","author":"Bager","year":"2024","journal-title":"PLoS One"},{"issue":"1","key":"10.1016\/j.cld.2026.04.007_bib33","doi-asserted-by":"crossref","DOI":"10.1136\/bmjgast-2020-000579","article-title":"Home-based exercise in patients with refractory fatigue associated with primary biliary cholangitis: a protocol for the EXerCise Intervention in cholesTatic LivEr Disease (EXCITED) feasibility trial","volume":"8","author":"Freer","year":"2021","journal-title":"BMJ Open Gastroenterol"},{"issue":"1","key":"10.1016\/j.cld.2026.04.007_bib34","doi-asserted-by":"crossref","first-page":"6","DOI":"10.1111\/liv.13919","article-title":"Fatigue in chronic liver disease: new insights and therapeutic approaches","volume":"39","author":"Swain","year":"2019","journal-title":"Liver Int"},{"key":"10.1016\/j.cld.2026.04.007_bib35","article-title":"Lipoprotein-X: a case of falsely elevated LDL hypercholesterolemia","volume":"13","author":"Mok","year":"2023","journal-title":"JACC Case Rep"},{"issue":"2","key":"10.1016\/j.cld.2026.04.007_bib36","doi-asserted-by":"crossref","first-page":"265","DOI":"10.1136\/gut.51.2.265","article-title":"Hyperlipidaemic state and cardiovascular risk in primary biliary cirrhosis","volume":"51","author":"Longo","year":"2002","journal-title":"Gut"},{"issue":"11","key":"10.1016\/j.cld.2026.04.007_bib37","doi-asserted-by":"crossref","first-page":"2116","DOI":"10.1194\/jlr.M400229-JLR200","article-title":"Lipoprotein-X reduces LDL atherogenicity in primary biliary cirrhosis by preventing LDL oxidation","volume":"45","author":"Chang","year":"2004","journal-title":"J Lipid Res"},{"issue":"2","key":"10.1016\/j.cld.2026.04.007_bib38","doi-asserted-by":"crossref","first-page":"293","DOI":"10.1016\/j.atherosclerosis.2006.11.036","article-title":"Primary biliary cirrhosis, hyperlipidemia, and atherosclerotic risk: a systematic review","volume":"194","author":"Sorokin","year":"2007","journal-title":"Atherosclerosis"},{"issue":"11","key":"10.1016\/j.cld.2026.04.007_bib39","doi-asserted-by":"crossref","first-page":"2784","DOI":"10.1111\/j.1572-0241.2008.02092.x","article-title":"Risk of cardiovascular and cerebrovascular events in primary biliary cirrhosis: a population-based cohort study","volume":"103","author":"Solaymani-Dodaran","year":"2008","journal-title":"Am J Gastroenterol"},{"issue":"6","key":"10.1016\/j.cld.2026.04.007_bib40","doi-asserted-by":"crossref","first-page":"879","DOI":"10.1016\/j.aohep.2019.07.006","article-title":"Patterns of serum lipids derangements and cardiovascular risk assessment in patients with primary biliary cholangitis","volume":"18","author":"Loaeza-Del Castillo","year":"2019","journal-title":"Ann Hepatol"},{"issue":"4","key":"10.1016\/j.cld.2026.04.007_bib41","doi-asserted-by":"crossref","first-page":"93","DOI":"10.4254\/wjh.v3.i4.93","article-title":"Asymptomatic primary biliary cirrhosis is not associated with increased frequency of cardiovascular disease","volume":"3","author":"Doycheva","year":"2011","journal-title":"World J Hepatol"},{"issue":"20","key":"10.1016\/j.cld.2026.04.007_bib42","doi-asserted-by":"crossref","first-page":"1348","DOI":"10.1016\/j.jaccas.2022.09.001","article-title":"Lipoprotein-X and Lipoprotein-Z induced hyperviscosity syndrome in the setting of cholestatic liver failure","volume":"4","author":"Waksman","year":"2022","journal-title":"JACC Case Rep"},{"issue":"4","key":"10.1016\/j.cld.2026.04.007_bib43","doi-asserted-by":"crossref","first-page":"305","DOI":"10.2217\/clp.15.23","article-title":"Management of lipoprotein X and its complications in a patient with primary sclerosing cholangitis","volume":"10","author":"Brandt","year":"2015","journal-title":"Clin Lipidol"},{"issue":"4","key":"10.1016\/j.cld.2026.04.007_bib44","doi-asserted-by":"crossref","first-page":"324","DOI":"10.1016\/j.jacl.2011.04.004","article-title":"Multiple lipoprotein and electrolyte laboratory artifacts caused by lipoprotein X in obstructive biliary cholestasis secondary to pancreatic cancer","volume":"5","author":"Sivakumar","year":"2011","journal-title":"J Clin Lipidol"},{"issue":"2","key":"10.1016\/j.cld.2026.04.007_bib45","doi-asserted-by":"crossref","first-page":"171","DOI":"10.1097\/00045391-200603000-00014","article-title":"Resolving hyperlipidemia after liver transplantation in a patient with primary sclerosing cholangitis","volume":"13","author":"Gandelman","year":"2006","journal-title":"Am J Therapeut"},{"issue":"1","key":"10.1016\/j.cld.2026.04.007_bib46","doi-asserted-by":"crossref","first-page":"88","DOI":"10.1186\/s12944-019-1041-4","article-title":"Impact of ursodeoxycholic acid on circulating lipid concentrations: a systematic review and meta-analysis of randomized placebo-controlled trials","volume":"18","author":"Simental-Mend\u00eda","year":"2019","journal-title":"Lipids Health Dis"},{"issue":"15","key":"10.1016\/j.cld.2026.04.007_bib47","doi-asserted-by":"crossref","first-page":"1182","DOI":"10.1161\/CIRCULATIONAHA.122.061578","article-title":"Very high cholesterol mimicking homozygous familial hypercholesterolemia","volume":"146","author":"Shotwell","year":"2022","journal-title":"Circulation"},{"issue":"5","key":"10.1016\/j.cld.2026.04.007_bib48","doi-asserted-by":"crossref","first-page":"613","DOI":"10.1111\/apt.18134","article-title":"The overlap with metabolic dysfunction-associated steatotic liver disease negatively affects outcomes of primary biliary cholangitis","volume":"60","author":"Hern\u00e1ndez-P\u00e9rez","year":"2024","journal-title":"Aliment Pharmacol Ther"},{"issue":"11","key":"10.1016\/j.cld.2026.04.007_bib49","doi-asserted-by":"crossref","first-page":"1333","DOI":"10.1080\/00365521.2020.1829030","article-title":"Serum vitamin D level is related to disease progression in primary biliary cholangitis","volume":"55","author":"Wang","year":"2020","journal-title":"Scand J Gastroenterol"},{"issue":"1","key":"10.1016\/j.cld.2026.04.007_bib50","doi-asserted-by":"crossref","first-page":"136","DOI":"10.1002\/hep.1840080126","article-title":"Impaired release of vitamin A from liver in primary biliary cirrhosis","volume":"8","author":"Nyberg","year":"1988","journal-title":"Hepatology"},{"issue":"9","key":"10.1016\/j.cld.2026.04.007_bib51","doi-asserted-by":"crossref","first-page":"2745","DOI":"10.1111\/j.1572-0241.2001.04134.x","article-title":"Fat-soluble vitamin levels in patients with primary biliary cirrhosis","volume":"96","author":"Phillips","year":"2001","journal-title":"Am J Gastroenterol"},{"issue":"1\u20132","key":"10.1016\/j.cld.2026.04.007_bib52","doi-asserted-by":"crossref","first-page":"141","DOI":"10.1007\/s12026-014-8594-0","article-title":"Vitamin D in primary biliary cirrhosis, a plausible marker of advanced disease","volume":"61","author":"Agmon-Levin","year":"2015","journal-title":"Immunol Res"},{"issue":"4","key":"10.1016\/j.cld.2026.04.007_bib53","doi-asserted-by":"crossref","first-page":"878","DOI":"10.3390\/nu14040878","article-title":"Vitamin D is associated with clinical outcomes in patients with primary biliary cholangitis","volume":"14","author":"Ebadi","year":"2022","journal-title":"Nutrients"},{"issue":"3","key":"10.1016\/j.cld.2026.04.007_bib54","doi-asserted-by":"crossref","first-page":"215","DOI":"10.1097\/00004836-199504000-00011","article-title":"Serum lipid and fat-soluble vitamin levels in primary sclerosing cholangitis","volume":"20","author":"Jorgensen","year":"1995","journal-title":"J Clin Gastroenterol"},{"issue":"3","key":"10.1016\/j.cld.2026.04.007_bib55","doi-asserted-by":"crossref","first-page":"537","DOI":"10.1016\/j.cld.2022.03.011","article-title":"Fat soluble vitamin assessment and supplementation in cholestasis","volume":"26","author":"Kamath","year":"2022","journal-title":"Clin Liver Dis"},{"issue":"9","key":"10.1016\/j.cld.2026.04.007_bib56","doi-asserted-by":"crossref","first-page":"1402","DOI":"10.1111\/j.1440-1746.2011.06746.x","article-title":"Relationships between blood levels of fat soluble vitamins and disease etiology and severity in adults awaiting liver transplantation","volume":"26","author":"Abbott-Johnson","year":"2011","journal-title":"J Gastroenterol Hepatol"},{"issue":"2","key":"10.1016\/j.cld.2026.04.007_bib57","first-page":"237","article-title":"Prevalence of fat-soluble vitamin (A, D, and E) and zinc deficiency in patients with cirrhosis being assessed for liver transplantation","volume":"80","author":"Teriaky","year":"2017","journal-title":"Acta Gastroenterol Belg"},{"issue":"6","key":"10.1016\/j.cld.2026.04.007_bib58","doi-asserted-by":"crossref","first-page":"627","DOI":"10.1002\/lt.23646","article-title":"High prevalence of vitamin A deficiency and vitamin D deficiency in patients evaluated for liver transplantation","volume":"19","author":"Venu","year":"2013","journal-title":"Liver Transpl"},{"issue":"13","key":"10.1016\/j.cld.2026.04.007_bib59","doi-asserted-by":"crossref","DOI":"10.3390\/nu17132167","article-title":"The role of vitamin D in inflammatory bowel diseases: from deficiency to targeted therapeutics and precise nutrition strategies","volume":"17","author":"Dell\u2019Anna","year":"2025","journal-title":"Nutrients"},{"issue":"2","key":"10.1016\/j.cld.2026.04.007_bib60","doi-asserted-by":"crossref","first-page":"221","DOI":"10.1111\/apt.13244","article-title":"Serum vitamin D level is associated with disease severity and response to ursodeoxycholic acid in primary biliary cirrhosis","volume":"42","author":"Guo","year":"2015","journal-title":"Aliment Pharmacol Ther"},{"issue":"3","key":"10.1016\/j.cld.2026.04.007_bib61","doi-asserted-by":"crossref","DOI":"10.3390\/nu15030576","article-title":"Prognostic significance of severe vitamin D deficiency in patients with primary sclerosing cholangitis","volume":"15","author":"Ebadi","year":"2023","journal-title":"Nutrients"},{"issue":"6","key":"10.1016\/j.cld.2026.04.007_bib62","doi-asserted-by":"crossref","first-page":"722","DOI":"10.1016\/j.clinre.2019.03.001","article-title":"The value of severe vitamin D deficiency in predicting the mortality risk of patients with liver cirrhosis: a meta-analysis","volume":"43","author":"Yang","year":"2019","journal-title":"Clin Res Hepatol Gastroenterol"},{"issue":"10","key":"10.1016\/j.cld.2026.04.007_bib63","article-title":"Vitamin D supplementation for chronic liver diseases in adults","volume":"2021","author":"Bjelakovic","year":"2021","journal-title":"Cochrane Database Syst Rev"},{"issue":"8","key":"10.1016\/j.cld.2026.04.007_bib64","doi-asserted-by":"crossref","DOI":"10.3390\/nu12082244","article-title":"Vitamin-D receptor-gene polymorphisms affect quality of life in patients with autoimmune liver diseases","volume":"12","author":"Kempinska-Podhorodecka","year":"2020","journal-title":"Nutrients"},{"issue":"5","key":"10.1016\/j.cld.2026.04.007_bib65","doi-asserted-by":"crossref","first-page":"4913","DOI":"10.1007\/s13277-014-1645-2","article-title":"Lack of association between vitamin D receptor gene ApaI, BsmI, and TaqI polymorphisms and primary biliary cirrhosis risk: a meta-analysis","volume":"35","author":"Mo","year":"2014","journal-title":"Tumor Biol"},{"issue":"4","key":"10.1016\/j.cld.2026.04.007_bib66","doi-asserted-by":"crossref","first-page":"706","DOI":"10.1111\/jgh.12443","article-title":"Polymorphisms in the vitamin D receptor gene and risk of primary biliary cirrhosis: a meta analysis","volume":"29","author":"Li","year":"2014","journal-title":"J Gastroenterol Hepatol"},{"issue":"1","key":"10.1016\/j.cld.2026.04.007_bib67","doi-asserted-by":"crossref","first-page":"145","DOI":"10.1016\/S0016-5085(00)70423-9","article-title":"Vitamin D-receptor genotypes as independent genetic predictors of decreased bone mineral density in primary biliary cirrhosis","volume":"118","author":"Springer","year":"2000","journal-title":"Gastroenterology"},{"issue":"2","key":"10.1016\/j.cld.2026.04.007_bib68","doi-asserted-by":"crossref","first-page":"282","DOI":"10.1136\/gut.49.2.282","article-title":"Osteoporosis in primary biliary cirrhosis revisited","volume":"49","author":"Newton","year":"2001","journal-title":"Gut"},{"issue":"3","key":"10.1016\/j.cld.2026.04.007_bib69","doi-asserted-by":"crossref","first-page":"306","DOI":"10.1097\/01.mcg.0000248017.31386.39","article-title":"Primary biliary cirrhosis is not an additional risk factor for bone loss in women receiving regular calcium and vitamin D supplementation","volume":"42","author":"Benetti","year":"2008","journal-title":"J Clin Gastroenterol"},{"issue":"3","key":"10.1016\/j.cld.2026.04.007_bib70","doi-asserted-by":"crossref","first-page":"316","DOI":"10.1016\/S0168-8278(01)00144-1","article-title":"Bone disease in primary biliary cirrhosis: independent indicators and rate of progression","volume":"35","author":"Menon","year":"2001","journal-title":"J Hepatol"},{"issue":"4","key":"10.1016\/j.cld.2026.04.007_bib71","doi-asserted-by":"crossref","first-page":"573","DOI":"10.1016\/j.jhep.2004.11.035","article-title":"Severity of cholestasis and advanced histological stage but not menopausal status are the major risk factors for osteoporosis in primary biliary cirrhosis","volume":"42","author":"Gua\u00f1abens","year":"2005","journal-title":"J Hepatol"},{"issue":"3","key":"10.1016\/j.cld.2026.04.007_bib72","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0194418","article-title":"Increased risk of osteoporosis in patients with primary biliary cirrhosis","volume":"13","author":"Liao","year":"2018","journal-title":"PLoS One"},{"issue":"7","key":"10.1016\/j.cld.2026.04.007_bib73","doi-asserted-by":"crossref","first-page":"2348","DOI":"10.1053\/j.gastro.2010.02.016","article-title":"Low bone mass and severity of cholestasis affect fracture risk in patients with primary biliary cirrhosis","volume":"138","author":"Gua\u00f1abens","year":"2010","journal-title":"Gastroenterology"},{"issue":"6","key":"10.1016\/j.cld.2026.04.007_bib74","doi-asserted-by":"crossref","first-page":"1752","DOI":"10.1053\/j.gastro.2006.09.012","article-title":"Fracture risk in people with primary biliary cirrhosis: a population-based cohort study","volume":"131","author":"Solaymani-Dodaran","year":"2006","journal-title":"Gastroenterology"},{"issue":"2","key":"10.1016\/j.cld.2026.04.007_bib75","doi-asserted-by":"crossref","first-page":"164","DOI":"10.1111\/joim.13624","article-title":"Risk of fractures and postfracture mortality in 3980 people with primary biliary cholangitis: a population based cohort study","volume":"294","author":"Sch\u00f6nau","year":"2023","journal-title":"J Intern Med"},{"issue":"1","key":"10.1016\/j.cld.2026.04.007_bib76","doi-asserted-by":"crossref","first-page":"180","DOI":"10.1053\/j.gastro.2010.10.014","article-title":"Bone disease in patients with primary sclerosing cholangitis","volume":"140","author":"Angulo","year":"2011","journal-title":"Gastroenterology"},{"issue":"5","key":"10.1016\/j.cld.2026.04.007_bib77","doi-asserted-by":"crossref","first-page":"941","DOI":"10.1016\/j.jhep.2018.12.035","article-title":"Th17 cell frequency is associated with low bone mass in primary sclerosing cholangitis","volume":"70","author":"Schmidt","year":"2019","journal-title":"J Hepatol"},{"issue":"2","key":"10.1016\/j.cld.2026.04.007_bib78","doi-asserted-by":"crossref","first-page":"659","DOI":"10.1002\/hep.32771","article-title":"AASLD practice guidance on primary sclerosing cholangitis and cholangiocarcinoma","volume":"77","author":"Bowlus","year":"2023","journal-title":"Hepatology"},{"issue":"3","key":"10.1016\/j.cld.2026.04.007_bib79","doi-asserted-by":"crossref","first-page":"761","DOI":"10.1016\/j.jhep.2022.05.011","article-title":"EASL clinical practice guidelines on sclerosing cholangitis","volume":"77","author":"Chazouilleres","year":"2022","journal-title":"J Hepatol"},{"issue":"4","key":"10.1016\/j.cld.2026.04.007_bib80","doi-asserted-by":"crossref","first-page":"895","DOI":"10.1053\/jhep.2002.36357","article-title":"Bone metabolism in advanced cholestatic liver disease: analysis by bone histomorphometry","volume":"36","author":"Guichelaar","year":"2002","journal-title":"Hepatology"},{"issue":"1","key":"10.1016\/j.cld.2026.04.007_bib81","doi-asserted-by":"crossref","first-page":"25","DOI":"10.1111\/j.1365-2362.2009.02230.x","article-title":"Lithocholic acid downregulates vitamin D effects in human osteoblasts","volume":"40","author":"Ruiz-Gasp\u00e0","year":"2010","journal-title":"Eur J Clin Invest"},{"issue":"6","key":"10.1016\/j.cld.2026.04.007_bib82","doi-asserted-by":"crossref","first-page":"2104","DOI":"10.1002\/hep.24605","article-title":"Effects of bilirubin and sera from jaundiced patients on osteoblasts: contribution to the development of osteoporosis in liver diseases","volume":"54","author":"Ruiz-Gasp\u00e0","year":"2011","journal-title":"Hepatology"},{"issue":"6","key":"10.1016\/j.cld.2026.04.007_bib83","doi-asserted-by":"crossref","first-page":"431","DOI":"10.1155\/2009\/635126","article-title":"Bone mineral densities in individuals with Gilbert\u2019s syndrome: a cross-sectional, case-control pilot study","volume":"23","author":"Minuk","year":"2009","journal-title":"Can J Gastroenterol"},{"key":"10.1016\/j.cld.2026.04.007_bib84","doi-asserted-by":"crossref","DOI":"10.1016\/j.bone.2022.116483","article-title":"Bilirubin increases viability and decreases osteoclast apoptosis contributing to osteoporosis in advanced liver diseases","volume":"162","author":"Jurado","year":"2022","journal-title":"Bone"},{"issue":"12","key":"10.1016\/j.cld.2026.04.007_bib85","doi-asserted-by":"crossref","first-page":"1206","DOI":"10.1111\/eci.12355","article-title":"Ursodeoxycholic acid decreases bilirubin-induced osteoblast apoptosis","volume":"44","author":"Ruiz-Gasp\u00e0","year":"2014","journal-title":"Eur J Clin Invest"},{"issue":"7","key":"10.1016\/j.cld.2026.04.007_bib86","doi-asserted-by":"crossref","first-page":"1029","DOI":"10.1111\/liv.12153","article-title":"Ursodeoxycholic acid increases differentiation and mineralization and neutralizes the damaging effects of bilirubin on osteoblastic cells","volume":"33","author":"Dubreuil","year":"2013","journal-title":"Liver Int"},{"issue":"2","key":"10.1016\/j.cld.2026.04.007_bib87","first-page":"389","article-title":"Bone disease in primary biliary cirrhosis: does ursodeoxycholic acid make a difference?\u22171","volume":"21","author":"LINDOR","year":"1995","journal-title":"Hepatology"},{"issue":"5","key":"10.1016\/j.cld.2026.04.007_bib88","doi-asserted-by":"crossref","first-page":"729","DOI":"10.1016\/S0168-8278(98)80253-5","article-title":"Bone disease in patients with primary sclerosing cholangitis: prevalence, severity and prediction of progression","volume":"29","author":"Angulo","year":"1998","journal-title":"J Hepatol"},{"issue":"6","key":"10.1016\/j.cld.2026.04.007_bib89","doi-asserted-by":"crossref","DOI":"10.1016\/j.aohep.2022.100746","article-title":"Prevalence and impact of Sj\u00f6gren\u2019s syndrome in primary biliary cholangitis: a systematic review and meta-analysis","volume":"27","author":"Deng","year":"2022","journal-title":"Ann Hepatol"}],"container-title":["Clinics in Liver Disease"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1089326126000413?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1089326126000413?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,7,22]],"date-time":"2026-07-22T23:36:06Z","timestamp":1784763366000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1089326126000413"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,8]]},"references-count":89,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2026,8]]}},"alternative-id":["S1089326126000413"],"URL":"https:\/\/doi.org\/10.1016\/j.cld.2026.04.007","relation":{},"ISSN":["1089-3261"],"issn-type":[{"value":"1089-3261","type":"print"}],"subject":[],"published":{"date-parts":[[2026,8]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"General Hepatology Concerns for the Patient with Cholestatic Liver Disease","name":"articletitle","label":"Article Title"},{"value":"Clinics in Liver Disease","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.cld.2026.04.007","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2026 Elsevier Inc. All rights are reserved, including those for text and data mining, AI training, and similar technologies.","name":"copyright","label":"Copyright"}]}}